Tiago Girao, Chief Financial Officer of Immunovant, Inc. (NASDAQ:IMVT), filed a Form 4 on October 30, 2026, disclosing the sale of 6,606 shares of common stock on October 28, 2026, to cover tax withholding obligations arising from the vesting of restricted stock units.

Key Highlights

  • Reporting person: Tiago Girao, Chief Financial Officer of Immunovant, Inc.
  • Transaction: 6,606 shares of common stock disposed of (transaction code S) on October 28, 2026.
  • Weighted average price: $28.50 per share, with individual sales ranging from $28.34 to $28.50 per share, inclusive.
  • Mandated sale: According to the filing, the sale was required by the issuer's "sell to cover" election and "does not represent a discretionary transaction by the Reporting Person."
  • RSU vesting: 13,024 RSUs from a May 1, 2025 grant of 208,388 RSUs vested on October 21, 2026.
  • Remaining ownership: Girao directly beneficially owned 234,192 shares of common stock following the reported transaction.

Immunovant CFO's RSU Vesting and Mandatory Tax-Cover Sale Details

According to the Form 4 filing, Tiago Girao, serving as Chief Financial Officer of Immunovant, Inc., sold 6,606 shares of the company's common stock on October 28, 2026. The filing states that the sale was connected to the vesting and settlement of restricted stock units originally granted on May 1, 2025, as previously reported on a Form 4 filed on May 5, 2025. Of the original grant of 208,388 RSUs, 13,024 vested on October 21, 2026.

The filing explains that the shares were sold to satisfy tax withholding obligations in connection with that vesting event. Specifically, the filing states the sale "is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person." The reported weighted average sale price was $28.50 per share, with individual transactions executed at prices ranging from $28.34 to $28.50 per share, inclusive. The filing notes that full information on shares sold at each separate price is available upon request to the issuer, any security holder, or SEC staff.

Following the reported transaction, Girao directly beneficially owned 234,192 shares of Immunovant common stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The Form 4 was signed by Tiago Girao and dated October 30, 2026.

What Was Disclosed

Immunovant CFO Tiago Girao filed a Form 4 reporting the mandatory sale of 6,606 common shares on October 28, 2026, at a weighted average of $28.50, to cover taxes owed upon the October 21, 2026 vesting of 13,024 RSUs. Post-transaction direct ownership stands at 234,192 shares.